Compare
PetVivo Holdings, Inc. vs RenovoRx, Inc. vs Sintx Technologies, Inc. vs Catheter Precision, Inc.
| Latest fiscal year | PetVivo Holdings, Inc. PETV | RenovoRx, Inc. RNXT | Sintx Technologies, Inc. SINT | Catheter Precision, Inc. VTAK |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.14M | $1.12M | $1.02M | $819.0K |
| Revenue growth (YoY) | +0.8% | n/m | -64.7% | +95.0% |
| Gross margin | 66.1% | 70.9% | 45.3% | 92.3% |
| Operating margin | -793.9% | n/m | n/m | n/m |
| Net margin | -917.4% | -994.5% | n/m | n/m |
| Net income | -$10.47M | -$11.17M | -$10.36M | -$17.18M |
| EPS (Diluted) | -$0.38 | -$0.32 | -$6.16 | n/a |
| Operating cash flow | -$6.11M | -$10.97M | -$8.57M | -$8.30M |
| Free cash flow | -$6.12M | -$10.97M | -$8.76M | -$8.31M |
| Cash & equivalents | n/a | $7.02M | $4.14M | $88.0K |
| Total assets | $3.58M | $8.10M | $9.51M | $15.86M |
| Total liabilities | $1.38M | $2.67M | $6.58M | $9.21M |
| Shareholders' equity | $2.20M | $5.42M | $2.93M | $7.05M |
| Return on year-end equity | -476.2% | -206.0% | -353.8% | -243.6% |
| Shares outstanding | 35.85M | 36.61M | 3.97M | 1.74M |
Revenue, most recent five fiscal years
| Fiscal year | PetVivo Holdings, Inc. | RenovoRx, Inc. | Sintx Technologies, Inc. | Catheter Precision, Inc. |
|---|---|---|---|---|
| Latest | $1.14M Ended 2026-03-31 | $1.12M Ended 2025-12-31 | $1.02M Ended 2025-12-31 | $819.0K Ended 2025-12-31 |
| 1 year earlier | $1.13M Ended 2025-03-31 | $43.0K Ended 2024-12-31 | $2.89M Ended 2024-12-31 | $420.0K Ended 2024-12-31 |
| 2 years earlier | $968.7K Ended 2024-03-31 | n/a | $2.63M Ended 2023-12-31 | $442.0K Ended 2023-12-31 |
| 3 years earlier | $917.2K Ended 2023-03-31 | n/a | $1.56M Ended 2022-12-31 | $14.0K Ended 2022-12-31 |
| 4 years earlier | $115.6K Ended 2022-03-31 | n/a | $606.0K Ended 2021-12-31 | $22.0K Ended 2021-12-31 |